{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:44:36Z","timestamp":1782719076796,"version":"3.54.5"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00259-026-07890-7","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T02:32:48Z","timestamp":1776306768000},"page":"5417-5426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of nephrotoxicity following lutetium-177 PSMA I&amp;T radioligand therapy: a comparative study with docetaxel chemotherapy"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5144-5531","authenticated-orcid":false,"given":"Florian P","family":"Kirchhoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Steinhelfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Pfob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Lapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp E.","family":"Hartrampf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schmaderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"F\u00fctterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Jahnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Knorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Lunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"7890_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/s0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804. https:\/\/doi.org\/10.1016\/s0140-6736(21)00237-3.","journal-title":"Lancet"},{"key":"7890_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"7890_CR3","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/s0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, et al. (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404:1227\u201339. https:\/\/doi.org\/10.1016\/s0140-6736(24)01653-2.","journal-title":"Lancet"},{"key":"7890_CR4","doi-asserted-by":"publisher","first-page":"1483953","DOI":"10.3389\/fonc.2024.1483953","volume":"14","author":"AR Hansen","year":"2024","unstructured":"Hansen AR, Probst S, Beauregard JM, Viglianti BL, Michalski JM, Tagawa ST, et al. Initial clinical experience with [(177)Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial. Front Oncol. 2024;14:1483953. https:\/\/doi.org\/10.3389\/fonc.2024.1483953.","journal-title":"Front Oncol"},{"key":"7890_CR5","unstructured":"Multi-Center A. Open-Label, Randomized phase 3 Trial comparing the safety and efficacy of 177Lu-PSMA-I&T versus hormone therapy in patients with metastatic castration-resistant prostate cancer. 2021. https:\/\/clinicaltrials.gov\/study\/NCT05204927."},{"key":"7890_CR6","doi-asserted-by":"publisher","first-page":"e546","DOI":"10.1016\/j.ijrobp.2024.07.1209","volume":"120","author":"H Kim","year":"2024","unstructured":"Kim H, Tagawa ST, Sartor AO, Saad F, Reid A, Sakharova O, et al. PSMAddition: Phase 3 Trial of [<\u2009sup>177\u2009lu]Lu-PSMA-617 Plus Standard of Care (SoC) vs. Soc Alone in Patients with Metastatic Hormone-Sensitive Prostate Cancer. Int J Radiat Oncol Biol Phys. 2024;120:e546. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.07.1209.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7890_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2967\/jnumed.123.265986","volume":"65","author":"L Steinhelfer","year":"2024","unstructured":"Steinhelfer L, Lunger L, Cala L, Pfob CH, Lapa C, Hartrampf PE, et al. Long-Term Nephrotoxicity of (177)Lu-PSMA Radioligand Therapy. J Nucl Med. 2024;65:79\u201384. https:\/\/doi.org\/10.2967\/jnumed.123.265986.","journal-title":"J Nucl Med"},{"key":"7890_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.123.266638","volume":"65","author":"AS Ravi Kumar","year":"2024","unstructured":"Ravi Kumar AS, Hofman MS. Unraveling the Impact of (177)Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation. J Nucl Med. 2024;65:85\u20136. https:\/\/doi.org\/10.2967\/jnumed.123.266638.","journal-title":"J Nucl Med"},{"key":"7890_CR9","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","volume":"75","author":"MM Heck","year":"2019","unstructured":"Heck MM, Tauber R, Schwaiger S, Retz M, D\u2019Alessandria C, Maurer T, et al. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with (177)Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019;75:920\u20136. https:\/\/doi.org\/10.1016\/j.eururo.2018.11.016.","journal-title":"Eur Urol"},{"key":"7890_CR10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604\u201312. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006.","journal-title":"Ann Intern Med"},{"key":"7890_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","volume":"75","author":"AS Levey","year":"2020","unstructured":"Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, et al. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020;75:84\u2013104. https:\/\/doi.org\/10.1053\/j.ajkd.2019.06.009.","journal-title":"Am J Kidney Dis"},{"key":"7890_CR12","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","volume":"64","author":"AS Levey","year":"2014","unstructured":"Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64:821\u201335. https:\/\/doi.org\/10.1053\/j.ajkd.2014.07.030.","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"7890_CR13","first-page":"s83","volume":"46","author":"R Valkema","year":"2005","unstructured":"Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005;46(Suppl 1):s83\u201391.","journal-title":"J Nucl Med"},{"key":"7890_CR14","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00259-017-3681-9","volume":"44","author":"A Yordanova","year":"2017","unstructured":"Yordanova A, Becker A, Eppard E, K\u00fcrpig S, Fisang C, Feldmann G, et al. The impact of repeated cycles of radioligand therapy using [(177)Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1473\u20139. https:\/\/doi.org\/10.1007\/s00259-017-3681-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7890_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-y","volume":"21","author":"B Emami","year":"1991","unstructured":"Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109\u201322. https:\/\/doi.org\/10.1016\/0360-3016(91)90171-y.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7890_CR16","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/s1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad AA, Bressel M, Tan H, Voskoboynik M, Suder A, Weickhardt AJ, et al. Sequential [(177)Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 2024;25:1267\u201376. https:\/\/doi.org\/10.1016\/s1470-2045(24)00440-6.","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07890-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07890-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07890-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:47:50Z","timestamp":1782715670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07890-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["7890"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07890-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Technical University Munich (references 115\/18S, 2020-40, 20200609 01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"There are no individual person\u2019s data published in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"ME reports fees from Blue Earth Diagnostics Ltd. (consultant, research funding), Novartis\/AAA (consultant, speaker), Telix (consultant), Bayer (consultant, research funding), RayzeBio (consultant), Point Biopharma (consultant), Eckert-Ziegler (speaker) and Janssen Pharmaceuticals (consultant, speakers bureau), Parexel (image review) and Bioclinica (image review) outside the submitted work and a patent application for rhPSMA. He and other inventors are entitled to royalties on sales of POSLUMA\n                      \u00ae\n                      . LL reports his employment at Boehringer Ingelheim International GmbH. CL reports prior consulting activities for Blue Earth Diagnostics Ltd., PentixaPharm, Pfizer, and Novartis. WW reports to be an editor in this journal.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The other authors declare no conflict of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}